Navigation Links
Jennerex Appoints James M. Burke, M.D. Vice President, Clinical Research
Date:2/22/2011

SAN FRANCISCO, Feb. 22, 2011 /PRNewswire/ -- Jennerex, Inc. (San Francisco), a clinical-stage cancer biotherapeutics company, today announced the appointment of James M. Burke, M.D. to the newly-created position of vice president, clinical research. Dr. Burke will be responsible for all global clinical research activities related to Jennerex pipeline compounds.

"Dr. Burke has been working with Jennerex in an advisory capacity as a clinical advisor for over a year, and has provided significant contributions to the strategic direction and clinical development of JX-594 for the treatment of liver cancer, and we look forward to bringing his expertise in-house," said David H. Kirn, M.D., president and chief executive officer of Jennerex. "In addition, as we advance our earlier stage pipeline products, Dr. Burke's direct clinical research experience using immunotherapeutics to treat multiple solid tumors will be instrumental as we pursue continued development of JX-929, JX-1395 and our next generation products."

Dr. Burke brings approximately 20 years of experience in basic and applied clinical science of genetic and immunotherapy.  His clinical research using immunotherapeutics including oncolytic viruses for the treatment of various cancers have advanced the understanding of the medical applications for oncolytic virus therapy. Prior to Jennerex, Dr. Burke was the Director of Cancer Research at Billings Clinic, where he was also a clinical investigator for JX-594. He had previously served as associate director of clinical research at Cell Genesys, Inc., where he was responsible for the development of the oncolytic adenovirus platform of agents and other gene therapy vaccines for the treatment of cancer and other diseases.  In addition, after completing his Hematology and Oncology Fellowship at UC San Francisco (UCSF), he was an attending physician at UCSF in the department of hematology and oncology. He received his M.D. from Georgeto
'/>"/>

SOURCE Jennerex, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Jennerex and Transgene Enter Into an Exclusive Partnership for the Development and Commercialization of JX-594 for the Treatment of Cancers
2. Jennerex Completes Fully Subscribed Private Placement for Aggregate Gross Proceeds of $8.6 Million
3. Jennerex Reports Positive Phase 1 Results for JX-594 Administered Intravenously
4. Jennerex Adds Industry Veteran Paul Cleveland to Board of Directors
5. Jennerex Completes Over-Subscribed Series C Financing for Aggregate Gross Proceeds of Over $5.5 Million
6. Jennerex Closes $5 Million First Tranche of Series C Financing
7. Nature Reviews Publishes Article About Jennerexs Multi-Mechanistic Cancer Therapeutic
8. Jennerex Appoints Samantha Miller as Vice President of Corporate Development
9. Jennerex Completes $8.3 Million Series B Financing and Appoints Dr. Cal Stiller as Director
10. ALS Therapy Development Institute Appoints Anil Godhwani to Board of Directors
11. Amarin Corporation Appoints Industry Veteran Paul E. Huff as Chief Commercial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... The report, "Synthetic Biology ... Cloning kits), Technology (Bioinformatics, Nanotechnology, Gene Synthesis, ... Bioremediation) - Global Forecast to 2018", analyses ... opportunities, and challenges. , Browse 99 market ... 185 pages and in-depth TOC of the ...
(Date:11/21/2014)... Arkansas (PRWEB) November 20, 2014 ... Pinnacle Ozone Solutions, LLC (Pinnacle), and PCI, Inc., ... announced that they have been selected to provide ... of Fayetteville, Arkansas Paul R. Noland Wastewater Treatment. ... BlueInGreen’s patented HyDOZ® gas dissolution technology, ...
(Date:11/21/2014)... Texas (PRWEB) November 21, 2014 ... Sodium Ferrocyanide Industry” is a professional and in-depth ... provides Sodium ferrocyanide information, like its definition, ... as industry overview. This report covers the international ... as global (such as the US, Europe, Asia, ...
(Date:11/21/2014)... , Nov. 20, 2014 Polaris ... been dosed in its Phase 1 trial of ... for the treatment of malignant pleural mesothelioma (MPM) ... is conducting clinical trials on ADI-PEG 20, both ... for the treatment of several other indications, including ...
Breaking Biology Technology:Synthetic Biology Market Expected to Reach $5,630.4 Million in 2018 - New Report by MarketsandMarkets 2Synthetic Biology Market Expected to Reach $5,630.4 Million in 2018 - New Report by MarketsandMarkets 3Synthetic Biology Market Expected to Reach $5,630.4 Million in 2018 - New Report by MarketsandMarkets 4City of Fayetteville Leads Nation with Innovative Ozone Technology 2City of Fayetteville Leads Nation with Innovative Ozone Technology 3City of Fayetteville Leads Nation with Innovative Ozone Technology 4Sodium Ferrocyanide Market: Analysis for Global & China Regions Development Trends Available at DeepResearchReports.com 2Sodium Ferrocyanide Market: Analysis for Global & China Regions Development Trends Available at DeepResearchReports.com 3Polaris Group Announces Treatment of First Patient in Phase 1 Study of ADI-PEG 20 plus Pemetrexed and Cisplatin in Malignant Pleural Mesothelioma And Non-Squamous Non-Small Cell Lung Carcinoma 2
... Advantages in Efficacy Will Drive Prescription Rates, According ... to a New Report ... Decision Resources, one of the,world,s leading research and advisory ... its approval in early 2009,Centocor/Janssen-Cilag,s ustekinumab will become the ...
... FRANCISCO, Feb. 13 BioSpace, the world,s leading,online ... company, hosted,over 1,000 biotechnology and pharmaceutical job candidates ... on Monday February 4, 2008., The BioSpace ... biotechnology,pharmaceutical, medical device, and diagnostics career candidates from,around ...
... antibody to be presented at AACR ... Special Conference on Cancer Stem Cells -, TORONTO, Feb. ... discovering and developing the next wave of,antibody therapeutics, today announced ... stem cell antibody will be,presented at the AACR Special Conference ...
Cached Biology Technology:Centocor/Janssen-Cilag's Ustekinumab Will Become the Gold Standard for Psoriasis By 2011 2BioSpace Career Fair in San Francisco Welcomes Over 1,000 Bioscience Professionals 2ARIUS presents new findings showing therapeutic antibody inhibits human leukemic cancer stem cells 2ARIUS presents new findings showing therapeutic antibody inhibits human leukemic cancer stem cells 3ARIUS presents new findings showing therapeutic antibody inhibits human leukemic cancer stem cells 4
(Date:11/7/2014)... , November 6, 2014 Leading ... for better mobile security revolutionizing online transactions.  Companies in focus ... Holdings Ltd. (NYSE: BABA ), Google Inc. (NASDAQ: ... ), eBay Inc. (NASDAQ: EBAY ) and MasterCard ... NXTD and NXTDW), a biometric authentication company focused on ...
(Date:11/5/2014)... in the UTSA College of Sciences, is one ... receive a two-year $300,00 National Science Foundation (NSF) ... funding supports President Obama,s BRAIN Initiative, a federal ... that will demystify complex brain processes. , ... broken into the interactions of multiple components, each ...
(Date:11/4/2014)... – Temple University School of Medicine announced today ... an initiative funded by the Bill & Melinda ... of Obstetrics, Gynecology and Reproductive Sciences; and Vice ... University School of Medicine will pursue an innovative ... Blood Biomarkers to Assess Fetal Neurodevelopment.", Grand Challenges ...
Breaking Biology News(10 mins):Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 2Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 3Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 4Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 5Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 6UTSA biology professor awarded $300,000 NSF grant for brain research 2UTSA biology professor awarded $300,000 NSF grant for brain research 3Temple University School of Medicine receives Grand Challenges Explorations grant 2
... Researchers at Polytechnic Institute of New York University ... the smallest single virus particles in solution, an advance ... setting and shrink test result wait times from weeks ... applied physics and member of the Othmer-Jacobs Department of ...
... an array of essential functions, including cell signaling, communication ... of cells. They are critical targets for drug delivery ... biomarkers early warning beacons announcing the pre-symptomatic presence ... the binding properties of membrane proteins is essential, detailed ...
... people can drop pounds quickly in the early phases of ... to keep the weight off in the long term. ... long-term weight loss even more challenging. A new study ... to weight loss in the short term are not effective ...
Cached Biology News:By detecting smallest virus, researchers open possibilities for early disease detection 2By detecting smallest virus, researchers open possibilities for early disease detection 3A new look at proteins in living cells 2A new look at proteins in living cells 3A new look at proteins in living cells 4Is long-term weight loss possible after menopause? 2Is long-term weight loss possible after menopause? 3
... peptide derived from the internal region of ... Specific for the internal region of the ... the target band at ~590 kDa. ... media from primary tracheobranchial epithelial cultures and ...
Lipid-rich bovine serum albumin for cell culture. It is chromatographically purified and has an IgG content 1.0% (w/w)....
Prepared with distilled water. Yeast extract solution is autolyzed at 150 g/L....
Request Info...
Biology Products: